DK0991660T3 - Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler - Google Patents

Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler

Info

Publication number: DK0991660T3
Authority: DK; Denmark
Prior art keywords: cyclosporine; substitution; disclosed; derivatives; unutilized
Prior art date: 1997-10-08

Application number

DK98947718T

Other languages

Danish (da)

English (en)

Inventor

Randall W Yatscoff

Robert T Foster

S Selvaraj Naicker

Original Assignee

Isotechnika Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-08

Filing date

1998-10-08

Publication date

2006-02-13

1998-10-08 Application filed by Isotechnika Inc filed Critical Isotechnika Inc

2006-02-13 Application granted granted Critical

2006-02-13 Publication of DK0991660T3 publication Critical patent/DK0991660T3/da

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 9
230000002519 immonomodulatory effect Effects 0.000 title 1
238000006467 substitution reaction Methods 0.000 abstract 4
229930105110 Cyclosporin A Natural products 0.000 abstract 3
108010036949 Cyclosporine Proteins 0.000 abstract 3
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
229910052805 deuterium Inorganic materials 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
230000001988 toxicity Effects 0.000 abstract 2
231100000419 toxicity Toxicity 0.000 abstract 2
108010036941 Cyclosporins Proteins 0.000 abstract 1
206010062016 Immunosuppression Diseases 0.000 abstract 1
125000003275 alpha amino acid group Chemical class 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
229930182912 cyclosporin Natural products 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
230000000155 isotopic effect Effects 0.000 abstract 1
230000004060 metabolic process Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biochemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Analytical Chemistry (AREA)
Pain & Pain Management (AREA)
Surgery (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Hematology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

DK98947718T 1997-10-08 1998-10-08 Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler DK0991660T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US6136097P	1997-10-08	1997-10-08

Publications (1)

Publication Number	Publication Date
DK0991660T3 true DK0991660T3 (da)	2006-02-13

Family

ID=22035297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98947718T DK0991660T3 (da)	1997-10-08	1998-10-08	Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler

Country Status (14)

Country	Link
US (3)	US6613739B1 (fr)
EP (1)	EP0991660B8 (fr)
JP (6)	JP4261049B2 (fr)
KR (1)	KR100585348B1 (fr)
AT (2)	ATE423130T1 (fr)
AU (1)	AU750245B2 (fr)
BR (1)	BR9811716A (fr)
CA (1)	CA2298572C (fr)
DE (2)	DE69840586D1 (fr)
DK (1)	DK0991660T3 (fr)
ES (1)	ES2256959T3 (fr)
NO (1)	NO324042B1 (fr)
NZ (1)	NZ502362A (fr)
WO (1)	WO1999018120A1 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
US20060025388A1 (en)	1999-04-30	2006-02-02	Glick Gary D	Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) *	1999-04-30	2009-08-11	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
JP5127096B2 (ja) *	1999-04-30	2013-01-23	ザリージェンツオブザユニバーシティオブミシガン	アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
US20050113460A1 (en) *	1999-04-30	2005-05-26	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) *	1999-04-30	2003-06-26	Regents Of The University Of Michigan	Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20040176358A1 (en) *	1999-04-30	2004-09-09	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
US6784156B2 (en)	2001-03-05	2004-08-31	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of respiratory diseases
US20030087813A1 (en)	2001-10-12	2003-05-08	Or Yat Sun	Cyclosporin analogs for the treatment of lung diseases
US6809077B2 (en)	2001-10-12	2004-10-26	Enanta Pharmaceuticals, Inc.	Cyclosporin analogs for the treatment of autoimmune diseases
AU2002333098B2 (en) *	2001-10-19	2006-03-16	Isotechnika Pharma Inc.	Novel cyclosporin analog microemulsion preconcentrates
PL210697B1 (pl) *	2001-10-19	2012-02-29	Isotechnika Inc	Kompozycja zawierająca mieszaninę izomerów analogu cyklosporyny i zastosowanie tej mieszaniny
EP1436321B9 (fr) *	2001-10-19	2008-11-12	Isotechnika Inc.	Synthese d'analogues de cyclosporine
US20040110666A1 (en) *	2002-12-04	2004-06-10	Or Yat Sun	Cyclosporins for the treatment of immune disorders
DE10261807A1 (de) *	2002-12-19	2004-07-01	Turicum Drug Development Ag	Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US7012065B2 (en)	2003-02-07	2006-03-14	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of immune disorders
JP2006524232A (ja)	2003-03-17	2006-10-26	アルバニーモレキュラーリサーチインコーポレーティッド	新規サイクロスポリン
TW200505946A (en) *	2003-04-08	2005-02-16	Hoffmann La Roche	Process for preparation of cyclosporin a analog
US20040266669A1 (en) *	2003-06-20	2004-12-30	Wu Frank X. H.	Cyclosporin derivatives for the treatment of immune disorders
TW200517114A (en)	2003-10-15	2005-06-01	Combinatorx Inc	Methods and reagents for the treatment of immunoinflammatory disorders
US7705036B2 (en) *	2004-04-01	2010-04-27	Cardiome Pharma Corp.	Deuterated aminocyclohexyl ether compounds and processes for preparing same
US7786119B2 (en) *	2004-04-01	2010-08-31	Cardiome Pharma Corp.	Drug conjugates of ion channel modulating compounds
US20050272723A1 (en) *	2004-04-27	2005-12-08	The Regents Of The University Of Michigan	Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) *	2004-04-27	2009-11-05	Regents Of The University Of Michigan	Methods and compositions for treating diseases and conditions associated with mitochondrial function
WO2006080951A2 (fr) *	2004-07-01	2006-08-03	Yale University	Materiaux polymeres charges de medicaments cibles a forte densite
US20060014677A1 (en) *	2004-07-19	2006-01-19	Isotechnika International Inc.	Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US7799756B2 (en) *	2004-07-29	2010-09-21	Albany Molecular Research, Inc.	Processes for stereoselective synthesis of trans ISATX247
US20060052369A1 (en) *	2004-09-07	2006-03-09	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
EP1804823A4 (fr) *	2004-09-29	2010-06-09	Amr Technology Inc	Nouveaux analogues de la cyclosporine et leurs utilisations pharmaceutiques
US7378391B2 (en)	2004-09-29	2008-05-27	Amr Technology, Inc.	Cyclosporin alkyne analogues and their pharmaceutical uses
JP2008515886A (ja)	2004-10-06	2008-05-15	エーエムアールテクノロジーインコーポレイテッド	シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
JP5159314B2 (ja)	2004-11-18	2013-03-06	カーディオムファーマコーポレイション	アミノシクロヘキシルエーテル化合物の合成方法
KR20070100284A (ko) *	2004-12-17	2007-10-10	이소테크니카 인코포레이티드	시클로스포린 유사체의 대사산물
CA2593019A1 (fr) *	2005-01-03	2006-07-13	The Regents Of The University Of Michigan	Compositions et procedes concernant de nouveaux composes et leurs cibles
CA2602732A1 (fr) *	2005-04-06	2006-10-12	Abbott Laboratories	Procedes permettant de mesurer les complexes immunosuppresseurs tacrolimus, sirolimus et cyclosporine a dans un prelevement sanguin
WO2007053193A2 (fr)	2005-06-01	2007-05-10	The Regents Of The University Of Michigan	Préparations de benzodiazépine non solvatées et méthodes
MX346530B (es) *	2005-06-15	2017-03-22	Cardiome Pharma Corp	Procedimiento sintético para la preparación de compuestos de éter aminociclohexílico.
WO2007041630A1 (fr) *	2005-10-06	2007-04-12	Auspex Pharmaceuticals, Inc.	Inhibiteurs deutériés d'atpase h+,k+ gastrique ayant des propriétés thérapeutiques renforcées
US20070105844A1 (en) *	2005-10-26	2007-05-10	Regents Of The University Of Michigan	Therapeutic compositions and methods
AU2006308655B2 (en)	2005-11-01	2010-09-23	The Regents Of The University Of Michigan	Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
NZ568694A (en)	2005-11-09	2011-09-30	Zalicus Inc	Method, compositions, and kits for the treatment of medical conditions
PL1954669T3 (pl)	2005-12-01	2016-01-29	Auspex Pharmaceuticals Inc	Podstawione fenetyloaminy o działaniu serotoninergicznym i/lub norepinefrynergicznym
GB0604647D0 (en)	2006-03-08	2006-04-19	Shchepinov Mikhail	Stabilized food supplements and their derivatives
US7696165B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7759338B2 (en) *	2006-04-27	2010-07-20	The Regents Of The University Of Michigan	Soluble 1,4 benzodiazepine compounds and stable salts thereof
US8155649B2 (en) *	2006-05-12	2012-04-10	Shared Spectrum Company	Method and system for classifying communication signals in a dynamic spectrum access system
WO2007146167A1 (fr)	2006-06-09	2007-12-21	The Regents Of The University Of Michigan	Compositions et procédés associés à de nouveaux composés et leurs cibles
US10265407B2 (en)	2007-02-15	2019-04-23	Yale University	Modular nanodevices for smart adaptable vaccines
US20100151436A1 (en) *	2007-03-02	2010-06-17	Fong Peter M	Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
KR101164718B1 (ko)	2007-03-09	2012-07-11	더 리젠츠 오브 더 유니버시티 오브 미시간	신규 화합물 및 이의 표적에 관한 조성물 및 방법
LT2125698T (lt)	2007-03-15	2016-10-10	Auspex Pharmaceuticals, Inc.	Deuterintas d9-venlafaksinas
CA2694329A1 (fr) *	2007-08-01	2009-02-05	Emory University	Procedes de determination d'une activite de proteine phosphatase et son utilisation dans la prediction de resultats therapeutiques
CN101855203B (zh)	2007-09-14	2014-03-19	密执安州立大学董事会	F1f0-atp合成酶抑制剂以及相关的方法
EP2217576B1 (fr)	2007-11-06	2016-05-11	The Regents of the University of Michigan	Composés benzodiazépinone utiles dans le traitement d'affections de la peau
JP2011514361A (ja)	2008-03-14	2011-05-06	レトロトップ、インコーポレイテッド	同位体で置換されたリジンを用いたがん治療
CA2730734C (fr) *	2008-07-15	2017-04-25	Theracos, Inc.	Composes de 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene deuterates presentant une activite inhibitrice de cotransporteur sodium-glucose
AU2009276241A1 (en)	2008-07-30	2010-02-04	Ciclofilin Pharmaceuticals Corp.	Nonimmunosuppressive cyclosporine analogue molecules
JP5586606B2 (ja) *	2008-09-02	2014-09-10	アクチミスファーマシューティカルズインコーポレーテッド	Ｃｒｔｈ２アンタゴニストとしての同位体富化されたピリミジン−５−イル酢酸誘導体
CN104311486A (zh) *	2008-09-03	2015-01-28	泰华制药工业有限公司	2-羰基-1,2-二氢喹啉免疫功能调节剂
EP2352724B1 (fr)	2008-09-11	2015-04-22	The Regents of the University of Michigan	Aryle guanidines comme inhibiteurs de la f1f0-atpase et leur utilisation medicale
CA2740952C (fr) *	2008-10-22	2015-12-29	Ian L. Scott	Composes de traitement de maladies et troubles ophtalmiques
RU2492181C2 (ru)	2009-01-30	2013-09-10	Энанта Фармасьютикалс, Инк.	Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
US8481483B2 (en)	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
WO2010121164A2 (fr)	2009-04-17	2010-10-21	The Regents Of The University Of Michigan	Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8685917B2 (en)	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8349312B2 (en)	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
JP2013505258A (ja)	2009-09-18	2013-02-14	ザリージェンツオブザユニバーシティオブミシガン	ベンゾジアゼピノン化合物およびそれを使用する治療方法
EP3536317A1 (fr)	2009-10-30	2019-09-11	Retrotope, Inc.	Soulagement des affections liées au stress oxydatif avec des dérivés d'acides gras polyinsaturés
EP2501387B1 (fr)	2009-11-17	2016-07-27	The Regents Of The University Of Michigan	1,4-benzodiazépine-2,5-diones et composés apparentés présentant des propriétés thérapeutiques
WO2011062766A2 (fr)	2009-11-17	2011-05-26	The Regents Of The University Of Michigan	1,4-benzodiazépine-2,5-diones et composés apparentés présentant des propriétés thérapeutiques
US20110130711A1 (en) *	2009-11-19	2011-06-02	Follica, Inc.	Hair growth treatment
UY33226A (es) *	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
KR102011339B1 (ko)	2010-12-15	2019-08-16	콘트라빌 파마슈티컬스, 인코퍼레이티드	아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자
WO2012145426A1 (fr)	2011-04-18	2012-10-26	The Trustees Of Columbia University In The City Of New York	Procédés pour traiter un cancer utilisant la cyclosporine et des dérivés de cyclosporine
EP2701695B1 (fr)	2011-04-26	2019-04-03	Retrotope, Inc.	Maladies neurodégénératives et maladies musculaires impliquant des acides gras polyinsaturés
EP2701698B1 (fr)	2011-04-26	2020-12-23	Retrotope, Inc.	Troubles impliquant l'oxydation des acides gras polyinsaturés (pufa)
WO2012148927A2 (fr)	2011-04-26	2012-11-01	Retrotope, Inc.	Troubles de traitement compromis de l'énergie et déficiences mitochondriales
EP3689342A1 (fr)	2011-04-26	2020-08-05	Retrotope, Inc.	Rétinopathies oxydatives
DE102011111991A1 (de)	2011-08-30	2013-02-28	Lead Discovery Center Gmbh	Neue Cyclosporin-Derivate
CN104053771B (zh)	2011-11-18	2016-11-09	科德克希思公司	用于制备羟基取代的氨基甲酸酯的生物催化剂
US9597385B2 (en)	2012-04-23	2017-03-21	Allertein Therapeutics, Llc	Nanoparticles for treatment of allergy
US8906853B2 (en)	2012-11-28	2014-12-09	Enanta Pharmaceuticals, Inc.	[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
AU2014248090B2 (en)	2013-04-03	2018-08-02	N-Fold Llc	Novel nanoparticle compositions
WO2015031381A1 (fr)	2013-08-26	2015-03-05	Enanta Pharmaceuticals, Inc.	Analogues de cyclosporine pour prévenir ou traiter une hépatite c
CA2935167C (fr)	2014-01-16	2022-02-22	Musc Foundation For Research Development	Nanosupports cibles pour l'administration d'agents immunosuppresseurs
US9669095B2 (en)	2014-11-03	2017-06-06	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues for preventing or treating hepatitis C infection
KR102643910B1 (ko)	2015-11-23	2024-03-06	레트로토프 인코포레이티드	1,4-다이엔 시스템에 대한 부위 특이적인 동위원소 표지법
WO2018106928A1 (fr)	2016-12-08	2018-06-14	Contravir Pharmaceuticals, Inc.	Traitement et prévention de maladies du vhb par des molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3
CA3087009A1 (fr)	2018-01-12	2019-07-18	Enb Therapeutics, Inc.	Composes deuteres, compositions et methodes de traitement de cancers associes a l'activation d'etbr
EP3867264A1 (fr)	2018-10-19	2021-08-25	Teva Pharmaceuticals International GmbH	Formes à l'état solide de la voclosporine
CA3172351A1 (fr)	2020-02-21	2021-08-26	Retrotope, Inc.	Procedes de modification isotopique d'acides gras polyinsatures et leurs derives
WO2021190601A1 (fr) *	2020-03-26	2021-09-30	Farsight Medical Technology (Shanghai) Co., Ltd.	Inhibiteurs de cyclophiline et leurs utilisations
US12109194B2 (en)	2021-02-05	2024-10-08	Biojiva Llc	Synergistic combination therapy for treating ALS
EP4201952A1 (fr)	2021-12-21	2023-06-28	Curia Spain, S.A.U.	Procédé de synthèse contrôlée de voclosporine
IT202300001116A1 (it) *	2023-01-25	2024-07-25	Indena Spa	Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
WO2025119925A1 (fr)	2023-12-05	2025-06-12	Medichem, S.A.	Procédé de préparation de voclosporine

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH614931A5 (fr)	1975-11-04	1979-12-28	Sandoz Ag
US4210581A (en)	1975-11-04	1980-07-01	Sandoz Ltd.	Organic compounds
US4117118A (en)	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
DE2819094A1 (de)	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv)	1978-10-18	1987-02-16	Sandoz Ag	Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en)	1979-03-12	1980-05-06	Merck & Co., Inc.	Antibiotic A43F
US4396542A (en)	1980-02-14	1983-08-02	Sandoz Ltd.	Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
DE3167014D1 (en)	1980-02-14	1984-12-13	Sandoz Ag	A method for the total synthesis of cyclosporins and novel cyclosporins
FR2487198A1 (fr)	1980-07-28	1982-01-29	Berri Balzac Sa	Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
US4384996A (en)	1981-01-09	1983-05-24	Sandoz Ltd.	Novel cyclosporins
CH667274A5 (de)	1984-03-23	1988-09-30	Sandoz Ag	Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NZ212051A (en)	1984-05-18	1988-10-28	Univ Australian	Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB8422253D0 (en)	1984-09-04	1984-10-10	Sandoz Ltd	Organic compounds
EP0194972B1 (fr)	1985-03-11	1992-07-29	Sandoz Ag	Cyclosporines
US4765980A (en)	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4764503A (en)	1986-11-19	1988-08-16	Sandoz Ltd.	Novel cyclosporins
HU205861B (en)	1986-12-19	1992-07-28	Sandoz Ag	Process for producing hydrosole of pharmaceutically effective material
EP0283801A3 (fr) *	1987-03-27	1990-05-30	Abbott Laboratories	Essais de polarisation par fluorescence pour cyclosporine A et les métabolites et immunogènes et anticorps apparentés
US5239057A (en)	1987-03-27	1993-08-24	Abbott Laboratories	Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US5427960A (en)	1987-03-27	1995-06-27	Abbott Laboratories	Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
US4798823A (en)	1987-06-03	1989-01-17	Merck & Co., Inc.	New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en)	1987-06-03	1989-12-05	Merck & Co., Inc.	Cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja)	1987-06-04	1997-01-29	三共株式会社	シクロスポリン製剤
ATE95193T1 (de) *	1987-06-17	1993-10-15	Sandoz Ag	Cyclosporine und deren benutzung als arzneimittel.
ATE110784T1 (de)	1987-06-19	1994-09-15	Sandoz Ag	Zyklische peptolide.
EP0373260B1 (fr)	1987-06-22	1994-03-09	Merck & Co. Inc.	Dérivés de cyclosporine avec un acide aminé modifié en position 8
GB8717300D0 (en)	1987-07-22	1987-08-26	Nat Res Dev	Cyclosporins
GB8717299D0 (en)	1987-07-22	1987-08-26	Nat Res Dev	Peptides
US5227467A (en)	1987-08-03	1993-07-13	Merck & Co., Inc.	Immunosuppressive fluorinated cyclosporin analogs
US4963362A (en)	1987-08-07	1990-10-16	Regents Of The University Of Minnesota	Freeze-dried liposome mixture containing cyclosporin
KR920003601B1 (ko)	1987-09-03	1992-05-04	유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드	점안 싸이클로스포린(cyclosporin)의 조성물
US4839342A (en)	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
US5089390A (en)	1987-09-04	1992-02-18	Syntex (U.S.A.) Inc.	2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US4914188A (en)	1987-11-16	1990-04-03	Merck & Co., Inc.	Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5236899A (en)	1987-11-16	1993-08-17	Merck & Co., Inc.	6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US5013719A (en)	1988-05-13	1991-05-07	Merrell Dow Pharmaceuticals Inc.	Method of effecting immunosuppression
KR0148748B1 (ko)	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US5342625A (en)	1988-09-16	1994-08-30	Sandoz Ltd.	Pharmaceutical compositions comprising cyclosporins
CA2004626A1 (fr)	1988-12-05	1990-06-05	Bernard F. Erlanger	Derives de la cyclosporine a, anticorps contre lesdits derives et application
US4996193A (en)	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5540931A (en)	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5284826A (en)	1989-07-24	1994-02-08	Sandoz Ltd.	0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5122511A (en)	1990-02-27	1992-06-16	Merck & Co., Inc.	Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5214130A (en)	1990-02-27	1993-05-25	Merck & Co., Inc.	Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
ATE132504T1 (de)	1990-08-15	1996-01-15	Abbott Lab	Immunotestreagenzien und verfahren zur bestimmung von cyclosporin
DE69124459T3 (de)	1990-11-02	2001-05-31	Novartis Ag, Basel	Zyklosporine
US5115859A (en)	1990-12-21	1992-05-26	United Technologies Corporation	Regenerable non-venting cooler for protective suit
DE59106428D1 (de)	1991-04-06	1995-10-12	Dresden Arzneimittel	Verfahren zur fermentativen Herstellung und Isolierung von Cyclosporin A sowie neue Cyclosporin- bildende Stämme.
GB9204466D0 (en) *	1992-03-02	1992-04-15	Sandoz Ltd	Improvements in or relating to organic compounds
HU213553B (en)	1992-05-25	1997-07-28	Biogal Gyogyszergyar	Process for isolating of cyclosporin-a
FI92334C (fi)	1992-12-30	1994-10-25	Leiras Oy	Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
AU674233B2 (en)	1993-05-04	1996-12-12	Merck & Co., Inc.	Cyclohexapeptidyl aminoalkyl ethers
ATE372966T1 (de) *	1994-03-25	2007-09-15	Isotechnika Inc	Verbesserung der effektivität von arzneimitteln duren deuterierung
US5639852A (en)	1994-09-01	1997-06-17	Wisconsin Alumni Research Foundation	Immunostimulatory agents
US5624902A (en)	1995-06-07	1997-04-29	Torrey Pines Institute For Molecular Studies	Peptide inhibitors of calmodulin
US5616595A (en)	1995-06-07	1997-04-01	Abbott Laboratories	Process for recovering water insoluble compounds from a fermentation broth
US5747330A (en)	1996-06-05	1998-05-05	Poli Industria Chimica	Antibiotic producing microbe
US5709797A (en)	1996-06-05	1998-01-20	Poli Industria Chimica S.P.A.	Method of isolating cyclosporins

1998
- 1998-10-08 EP EP98947718A patent/EP0991660B8/fr not_active Expired - Lifetime
- 1998-10-08 AT AT05024216T patent/ATE423130T1/de not_active IP Right Cessation
- 1998-10-08 CA CA002298572A patent/CA2298572C/fr not_active Expired - Lifetime
- 1998-10-08 DE DE69840586T patent/DE69840586D1/de not_active Expired - Fee Related
- 1998-10-08 ES ES98947718T patent/ES2256959T3/es not_active Expired - Lifetime
- 1998-10-08 BR BR9811716-5A patent/BR9811716A/pt not_active Application Discontinuation
- 1998-10-08 DE DE69832984T patent/DE69832984T2/de not_active Expired - Lifetime
- 1998-10-08 JP JP2000514928A patent/JP4261049B2/ja not_active Expired - Lifetime
- 1998-10-08 KR KR1020007003743A patent/KR100585348B1/ko not_active Expired - Fee Related
- 1998-10-08 NZ NZ502362A patent/NZ502362A/en not_active IP Right Cessation
- 1998-10-08 WO PCT/IB1998/001693 patent/WO1999018120A1/fr active IP Right Grant
- 1998-10-08 DK DK98947718T patent/DK0991660T3/da active
- 1998-10-08 AT AT98947718T patent/ATE314388T1/de active
- 1998-10-08 AU AU94542/98A patent/AU750245B2/en not_active Expired
2000
- 2000-02-29 NO NO20001020A patent/NO324042B1/no not_active IP Right Cessation
- 2000-08-07 US US09/634,945 patent/US6613739B1/en not_active Expired - Lifetime
- 2000-08-14 US US09/639,708 patent/US6605593B1/en not_active Expired - Lifetime
2001
- 2001-11-07 US US09/985,997 patent/US20020132763A1/en not_active Abandoned
2003
- 2003-10-17 JP JP2003358524A patent/JP2004143168A/ja not_active Withdrawn
2005
- 2005-08-11 JP JP2005233674A patent/JP2005343904A/ja not_active Withdrawn
2007
- 2007-01-26 JP JP2007017196A patent/JP2007119489A/ja not_active Withdrawn
2008
- 2008-05-27 JP JP2008138790A patent/JP2008222725A/ja not_active Withdrawn
- 2008-05-27 JP JP2008138789A patent/JP2008222724A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69832984D1 (de)	2006-02-02
CA2298572A1 (fr)	1999-04-15
EP0991660B8 (fr)	2006-04-05
US6613739B1 (en)	2003-09-02
US6605593B1 (en)	2003-08-12
NO20001020L (no)	2000-02-29
JP4261049B2 (ja)	2009-04-30
AU750245B2 (en)	2002-07-11
CA2298572C (fr)	2002-04-09
EP0991660A1 (fr)	2000-04-12
DE69832984T2 (de)	2006-09-21
NO20001020D0 (no)	2000-02-29
JP2007119489A (ja)	2007-05-17
NO324042B1 (no)	2007-07-30
ATE314388T1 (de)	2006-01-15
ES2256959T3 (es)	2006-07-16
JP2008222724A (ja)	2008-09-25
NZ502362A (en)	2001-05-25
US20020132763A1 (en)	2002-09-19
BR9811716A (pt)	2000-07-18
DE69840586D1 (de)	2009-04-02
EP0991660B1 (fr)	2005-12-28
HK1026432A1 (en)	2000-12-15
KR100585348B1 (ko)	2006-06-01
JP2008222725A (ja)	2008-09-25
JP2005343904A (ja)	2005-12-15
JP2004143168A (ja)	2004-05-20
AU9454298A (en)	1999-04-27
WO1999018120A1 (fr)	1999-04-15
KR20010030978A (ko)	2001-04-16
JP2001519355A (ja)	2001-10-23
ATE423130T1 (de)	2009-03-15

Publication	Publication Date	Title
DK0991660T3 (da)	2006-02-13	Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler
Kruger et al.	1999	Electron capture dissociation of multiply charged peptide cations
Kenny et al.	1992	Fragmentation studies of peptides: the formation of y ions
AU9315398A (en)	1999-03-29	Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
WO2003031464A3 (fr)	2006-03-02	Remodelage et glycoconjugaison de peptides
HUP0002381A1 (hu)	2000-10-28	Apolipoprotein A-1 agonista hatású peptidszármazékok, ezek lipidekkel alkotott komplexei, valamint ezeket tartalmazó gyógyászati készítmények
DE69912952D1 (en)	2003-12-24	Cyclosporine
WO2004099231A3 (fr)	2006-03-16	Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
IL128829A0 (en)	2000-01-31	Improved solid-phase peptide and agent for use in such synthesis
ID21956A (id)	1999-08-19	Asam n-(aril dan atau heteroarilasetil) amino ester, komposisi farmasi yang mengandungnya, dan metoda untuk menghambat pelepasan betha-amiloid peptida dan atau sintesanya dengan menggunakan senyawa tersebut
WO1996034107A3 (fr)	1997-04-24	Proteines antivirales, sequences d'adn codant pour ces proteines et utilisations
NO961075L (no)	1996-03-15	Krystallinsk, vannfritt mykofenolatmofetil og intravenöst preparat derav
WO1995011309A3 (fr)	1995-06-08	Nouvelle phosphoproteine nucleaire mitotique appelee mitosine
ATE330968T1 (de)	2006-07-15	Cyclosporin-derivate und verfahren zu deren herstellung
EP0174279A3 (fr)	1989-01-25	Thérapie de la cyclosporine
NO995481L (no)	1999-11-09	Glykokonjugater av 20 (S)-camptothecin
BR0312889A (pt)	2005-06-14	Polipeptìdeo t20 peguilado
BR9407693A (pt)	1997-02-04	Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
WO2000058456A3 (fr)	2001-02-15	Compositions et methodes permettant de modifier les effets toxiques de composes proteiques
WO2004091475A3 (fr)	2007-04-19	Medicaments pour la maladie de gaucher et procedes d'identification de ces medicaments
WO1996028468A3 (fr)	1997-04-17	Peptides amphiphiles et analogues desdits peptides
AU6415994A (en)	1994-10-24	Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
IT1319674B1 (it)	2003-10-23	Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
CA2511888A1 (fr)	1999-04-15	Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs
CA2372639A1 (fr)	1999-04-15	Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs